Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $22.2 million.

  • Abeona Therapeutics' Total Current Liabilities rose 2039.95% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 2039.95%. This contributed to the annual value of $16.6 million for FY2024, which is 2358.07% up from last year.
  • Abeona Therapeutics' Total Current Liabilities amounted to $22.2 million in Q3 2025, which was up 2039.95% from $34.5 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Total Current Liabilities peaked at $41.9 million during Q2 2021, and registered a low of $7.4 million during Q1 2023.
  • Over the past 5 years, Abeona Therapeutics' median Total Current Liabilities value was $16.6 million (recorded in 2024), while the average stood at $18.4 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Total Current Liabilities plummeted by 6979.11% in 2022, and later surged by 11899.67% in 2024.
  • Over the past 5 years, Abeona Therapeutics' Total Current Liabilities (Quarter) stood at $16.6 million in 2021, then tumbled by 53.2% to $7.8 million in 2022, then surged by 72.54% to $13.4 million in 2023, then grew by 23.58% to $16.6 million in 2024, then soared by 33.72% to $22.2 million in 2025.
  • Its last three reported values are $22.2 million in Q3 2025, $34.5 million for Q2 2025, and $18.0 million during Q1 2025.